DK1015413T3 - Anvendelse af en ingenanforbindelse til fremstilling af et lægemiddel til behandling af cancer - Google Patents

Anvendelse af en ingenanforbindelse til fremstilling af et lægemiddel til behandling af cancer

Info

Publication number
DK1015413T3
DK1015413T3 DK98938534T DK98938534T DK1015413T3 DK 1015413 T3 DK1015413 T3 DK 1015413T3 DK 98938534 T DK98938534 T DK 98938534T DK 98938534 T DK98938534 T DK 98938534T DK 1015413 T3 DK1015413 T3 DK 1015413T3
Authority
DK
Denmark
Prior art keywords
compound
compounds
euphorbia
jatrophanes
plants
Prior art date
Application number
DK98938534T
Other languages
Danish (da)
English (en)
Inventor
James Harrison Aylward
Original Assignee
Peplin Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3802927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1015413(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Peplin Research Pty Ltd filed Critical Peplin Research Pty Ltd
Application granted granted Critical
Publication of DK1015413T3 publication Critical patent/DK1015413T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK98938534T 1997-08-19 1998-08-19 Anvendelse af en ingenanforbindelse til fremstilling af et lægemiddel til behandling af cancer DK1015413T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO8640A AUPO864097A0 (en) 1997-08-19 1997-08-19 Anti-cancer compounds
PCT/AU1998/000656 WO1999008994A1 (en) 1997-08-19 1998-08-19 Anti-cancer compounds

Publications (1)

Publication Number Publication Date
DK1015413T3 true DK1015413T3 (da) 2008-09-22

Family

ID=3802927

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98938534T DK1015413T3 (da) 1997-08-19 1998-08-19 Anvendelse af en ingenanforbindelse til fremstilling af et lægemiddel til behandling af cancer

Country Status (17)

Country Link
US (4) US6432452B1 (de)
EP (1) EP1015413B1 (de)
JP (3) JP2001515059A (de)
CN (1) CN1266421B (de)
AT (1) ATE397580T1 (de)
AU (1) AUPO864097A0 (de)
BE (1) BE2013C026I2 (de)
BR (1) BR9811327A (de)
CA (1) CA2301082C (de)
CY (2) CY1108303T1 (de)
DE (1) DE69839586D1 (de)
DK (1) DK1015413T3 (de)
ES (1) ES2308810T3 (de)
HU (2) HU228862B1 (de)
LU (1) LU92185I2 (de)
PT (1) PT1015413E (de)
WO (1) WO1999008994A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO864097A0 (en) * 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US7078434B1 (en) * 1999-08-12 2006-07-18 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Use of Ginkgo extract
AU748542B2 (en) * 2000-06-07 2002-06-06 Leo Laboratories Limited Therapeutic agents - III
AUPQ801700A0 (en) * 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
AUPQ923100A0 (en) * 2000-08-07 2000-08-31 Peplin Research Pty Ltd Treatment of prostate cancer
US6923993B2 (en) * 2001-12-12 2005-08-02 Nicholas J. Donato Process of isolating extract from the Euphorbia obesa plant and methods for using the same
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
ATE466074T1 (de) 2003-10-14 2010-05-15 Baxter Int Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
CA2556550A1 (en) * 2004-02-17 2005-09-01 University Of South Florida Cytotoxin compound and method of isolation
JP5650367B2 (ja) * 2004-02-27 2015-01-07 アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物
DE102004044428A1 (de) * 2004-09-14 2006-03-30 Toximed Gmbh Verfahren und pharmazeutischer Wirkstoff zur Bekämpfung von Plasmodien
EP1838330A4 (de) 2004-12-13 2010-07-07 Peplin Research Pty Ltd Behandlung von soliden tumoren
AU2005316185B2 (en) * 2004-12-13 2012-04-12 Leo Laboratories Limited Treatment of solid cancers
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006134609A2 (en) * 2005-06-16 2006-12-21 Mmi Corporation Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions thereof
US7655620B2 (en) * 2005-07-07 2010-02-02 Cancure Laboratories, Llc Use of one or more metal carriers to selectively kill mammalian cells
EA200800321A1 (ru) * 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
US9597311B2 (en) * 2005-09-27 2017-03-21 Robert Benson Aylor Suppression and prevention of tumors
KR20080077625A (ko) * 2005-11-25 2008-08-25 페플린 리서치 피티이 리미티드 상처 치유 방법
WO2007065925A2 (de) * 2005-12-07 2007-06-14 Toximed Gmbh Zusammensetzung zur behandlung von melanomen und hautunreinheiten sowie kosmetisches hautpflegemittel
GB0525680D0 (en) 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080069809A1 (en) * 2006-04-20 2008-03-20 Ogbourne Steven M Compositions and methods for the diagnosis and treatment of cancer
US20080207738A1 (en) * 2007-02-28 2008-08-28 Cancure Laboratories, Llc Drug combinations to treat drug resistant tumors
TWI389699B (zh) * 2009-02-13 2013-03-21 高雄醫學大學 用於誘導細胞凋亡之樟芝子實體乙醇萃取物及其製備方法
JP5638008B2 (ja) * 2009-02-13 2014-12-10 レオ・ラボラトリーズ・リミテッドＬｅｏ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｉｍｉｔｅｄ 皮膚治療方法
EP2558435B1 (de) * 2010-04-16 2017-06-07 Leo Pharma A/S Orthorhombisch kristallines ingenolmebutat
WO2011139172A1 (en) * 2010-05-06 2011-11-10 Goran Milosavljevic Diterpene compounds with antineoplastic activities and pharmaceutical compositions comprising same
AU2011323832B2 (en) * 2010-10-25 2016-06-02 Niiki Pharma Inc. Method of treating neuroendocrine tumors
US9402823B2 (en) 2010-12-17 2016-08-02 Leo Laboratories Limited Ingenols for treating seborrheic keratosis
JP2014507396A (ja) 2010-12-22 2014-03-27 レオ・ラボラトリーズ・リミテッド イノゲノール−３−アシラートｉ
RU2572549C2 (ru) 2010-12-22 2016-01-20 Лео Лэборетериз Лимитед Ингенол-3-ацилаты iii и ингенол-3-карбаматы
CN103402969A (zh) 2010-12-22 2013-11-20 利奥实验室有限公司 3-酰基-巨大戟二萜醇ii
US8858953B2 (en) 2011-05-09 2014-10-14 Yu-Hwa Peter Sheng Herbal composition for treating cancer
WO2012176015A1 (en) 2011-06-24 2012-12-27 Leo Pharma A/S Methods for treating uv-damaged skin and scc tumors and for removing tattoos with topical ingenol mebutate
KR101374760B1 (ko) * 2011-10-26 2014-03-17 한국생명공학연구원 포볼 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물
CA2875461A1 (en) 2012-06-26 2014-01-03 Xifu Liang 3-o-heteroaryl-ingenol
CN103655674A (zh) * 2012-09-11 2014-03-26 清华大学深圳研究生院 乳浆大戟提取物及其制备方法和应用
KR101578404B1 (ko) 2014-03-18 2015-12-18 원광대학교 산학협력단 대극속 식물 추출물 또는 분획물을 유효성분으로 포함하는 암 예방 또는 치료용 조성물
CN107210718A (zh) * 2014-11-20 2017-09-26 迪芬尼香港有限公司 使用多速率fir和全通iir滤波器均衡扬声器系统的声学响应的方法和装置
CN106947460A (zh) * 2015-10-01 2017-07-14 钱秀英 用于判断时间的生物显色剂
CN106928995A (zh) * 2015-10-01 2017-07-07 钱秀英 基于生物显色技术以服务于物联网的储物箱
US12502369B2 (en) 2015-11-11 2025-12-23 K-Gen, Inc. Methods of cancer treatment
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2018044242A1 (en) 2016-09-02 2018-03-08 Thailand Centre Of Excellence For Life Sciences Method for preparing an extract of hevea latex and composition thereof
CN110663685B (zh) * 2019-10-23 2021-10-12 扬州大学 一种介孔二氧化硅负载ppte的纳米农药制剂
CN112441924B (zh) * 2020-12-11 2024-05-03 浙江工业大学 巨大戟二萜化合物及其提取方法与应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2902506A1 (de) * 1979-01-23 1980-07-24 Deutsches Krebsforsch Verwendung von nicht oder nur gering irritierenden und/oder promovierenden diterpenalkoholen und von derivaten davon als antineoplastische mittel
JPS5813571A (ja) * 1981-07-14 1983-01-26 Sagami Chem Res Center ジヒドロフラン誘導体及びその製造方法
US4418064A (en) 1982-09-29 1983-11-29 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone
US4560774A (en) 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
US5886019A (en) 1986-06-11 1999-03-23 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. F.
US5891870A (en) 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Protein kinase C modulators Q
US5145842A (en) 1986-06-11 1992-09-08 Alder Research Center Limited Partnership Protein kinase c. modulators. d.
US5750568A (en) 1986-06-11 1998-05-12 Procyon Pharmaceuticals, Inc. Protein kinase C Modulators. L.
US5643948A (en) 1986-06-11 1997-07-01 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. K.
US5891906A (en) 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Polyacetate-derived phorboids having anti-inflammatory and other uses
US5886017A (en) 1986-06-11 1999-03-23 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. E.
IL82811A0 (en) 1986-06-11 1987-12-20 Alder Res Center Corp Anti-inflammatory compositions containing methanol derivatives and novel compounds contained therein
US5716968A (en) 1986-06-11 1998-02-10 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. H.
DE3805965A1 (de) 1988-02-25 1989-09-07 Tamas Geb Szenasi Eszter Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe
DE4102054A1 (de) 1991-01-24 1992-07-30 Geb Szenasi Tamas Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe
CN1047084C (zh) 1993-03-30 1999-12-08 刘振宪 人参口服液及其制造方法
US6593371B1 (en) * 1993-05-19 2003-07-15 Jeff J. Staggs Treatment for wart and related disorders
CN1048164C (zh) 1993-08-24 2000-01-12 吴雪姣 复方菝葜口服液
JP2913451B2 (ja) 1994-06-22 1999-06-28 株式会社イナックス 防水パンの高さ調整構造
JPH08245505A (ja) * 1994-09-09 1996-09-24 Tosoh Corp ジテルペン誘導体、その製造法及びそれを有効成分として含有する抗腫瘍剤
JPH08176002A (ja) 1994-12-27 1996-07-09 Kao Corp 細胞接着抑制剤
CN1070372C (zh) 1995-02-15 2001-09-05 赵国强 强力抗癌膏及其制造方法
WO1997015575A1 (en) 1995-10-27 1997-05-01 Procyon Pharmaceuticals, Inc. Protein kinase c modulators. y.
CN1058620C (zh) * 1995-11-12 2000-11-22 卢颖 一种治疗癌症的外用中成药及配备生产工艺
JPH08268961A (ja) * 1996-02-28 1996-10-15 Procyon Pharmaceut Inc 抗炎症組成物
US5932613A (en) * 1996-07-03 1999-08-03 Millennium Pharmaceuticals, Inc. Anticancer agents
AUPO864097A0 (en) * 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
JP2001139468A (ja) * 1999-11-11 2001-05-22 Lead Chemical Co Ltd 抗ウイルス作用を有するホルボール誘導体
US6444555B2 (en) * 1999-12-07 2002-09-03 Advanced Micro Devices, Inc. Method for establishing ultra-thin gate insulator using anneal in ammonia
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
AUPQ923100A0 (en) * 2000-08-07 2000-08-31 Peplin Research Pty Ltd Treatment of prostate cancer
US20030185168A1 (en) * 2002-03-28 2003-10-02 Yu-Wei Tung Topology of frequency converting blocks of wireless lan access point

Also Published As

Publication number Publication date
BR9811327A (pt) 2000-09-19
HUP0004262A1 (hu) 2001-08-28
CN1266421A (zh) 2000-09-13
CN1266421B (zh) 2014-06-18
EP1015413A4 (de) 2004-01-28
EP1015413A1 (de) 2000-07-05
LU92185I2 (fr) 2014-04-23
AU8721798A (en) 1999-03-08
US7410656B2 (en) 2008-08-12
US20020076457A1 (en) 2002-06-20
CY2013020I2 (el) 2019-11-27
US6432452B1 (en) 2002-08-13
CY1108303T1 (el) 2014-02-12
EP1015413B1 (de) 2008-06-04
CA2301082C (en) 2009-02-03
ATE397580T1 (de) 2008-06-15
US20010051644A1 (en) 2001-12-13
AUPO864097A0 (en) 1997-09-11
WO1999008994A1 (en) 1999-02-25
US20050003031A1 (en) 2005-01-06
CA2301082A1 (en) 1999-02-25
JP2015007130A (ja) 2015-01-15
HU228862B1 (en) 2013-06-28
BE2013C026I2 (en) 2018-06-05
DE69839586D1 (de) 2008-07-17
JP2012031212A (ja) 2012-02-16
HUS1300063I1 (hu) 2019-11-28
ES2308810T3 (es) 2008-12-01
PT1015413E (pt) 2008-09-15
US6787161B2 (en) 2004-09-07
AU736230B2 (en) 2001-07-26
CY2013020I1 (el) 2019-11-27
US6844013B2 (en) 2005-01-18
JP2001515059A (ja) 2001-09-18

Similar Documents

Publication Publication Date Title
DK1015413T3 (da) Anvendelse af en ingenanforbindelse til fremstilling af et lægemiddel til behandling af cancer
DE3689363D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung der Metastasen von Krebstumoren.
DE69838099D1 (de) Quinazolinenon-enthaltende pharmazeutische zusammensetzungen zur verhütung von gefässneubildung und zur behandlung von bösartigen neubildungen
MX9202181A (es) Compuestos arilicos y heteroarilicos bis mono y biciclicos que inhiben la tirosina quinasa de receptor de egf y/o pdgf.
AU7031500A (en) Therapeutic quinazoline compounds
DK0954299T3 (da) Thyroxin-analoger uden signifikant hormonal aktivitet til behandling af ondartede tumorer
PT97638A (pt) Processo para a preparacao de compostos peptidicos e de composicoes farmaceuticas que os contem
AU646230B2 (en) Pharmaceutical compositions and methods for treating the symptoms of overindulgence
TR199902606T2 (xx) Farnesil transferaz� engelleyici kinazolinonlar.
IS2750B (is) Leiðarafesting
GB2363985B (en) Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
DE69637178D1 (de) N-chlorphenylcarbamate enthaltendes arzneimittel sowie n-chlorphenylthiocarbamate zur hemmung des wachstums von viren
GB9907571D0 (en) Compounds
ATE91237T1 (de) Kombinationen von nekrose-tumor-faktoren und entzuendungshemmenden mitteln fuer die behandlung von boesartigen und nicht boesartigen erkrankungen.
MX9702037A (es) Metodo para minimizar el efecto uterotrofico de tamoxifeno y analogos de tamoxifeno.
NO932843D0 (no) Farmasoeytiske preparater
DE69218200D1 (de) Behandlung von leberkrebs
BR0015122A (pt) Composição farmacêutica, e, método de tratamento de inflamação
DE60113418D1 (de) Anti-karzinogene aktivität von aus der lakritzenwurzel isolierten hydroxylierten chalcon-verbindungen
ES2182524T3 (es) Composiciones de hidroxiomeprazol y sus utilizaciones.
ATE169819T1 (de) (-)-metrifonat enthaltendes arzneimittel
WO2001007029A3 (en) Substituted guanidines and the use thereof
ATE346080T1 (de) Steroid-verbindungen mit anti-tumoraler wirkung
ATE263556T1 (de) Phenylessigsäure enthaltende zusammensetzungen zur behandlung und vorbeugung der atherosklerose und der restenose
IT1190942B (it) Composto ad attivita' analgesica ed antiinfiammatoria,suo procedimento di preparazione e relative composizioni farmaceutiche